AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20875372 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally dosed azithromycin
Number of subjects: 160
Study 17032712 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 mug twice a day
Number of subjects: 489
Study 17032712 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol + ET/HT
Number of subjects: 489
Study 17032712 — intervention group
Group type: EXPERIMENTAL
Intervention: ET/HT
Number of subjects: 489
Study 17032712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 15784801 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma writing group
Number of subjects: 92
Study 15784801 — intervention group
Group type: COMPARATOR
Intervention: Control writing group
Number of subjects: 92
Study 15784801 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 92
Study 12208905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone autograft
Number of subjects: 56
Study 12208905 — intervention group
Group type: COMPARATOR
Intervention: Two-strand semitendinosus-gracilis autograft
Number of subjects: 56
Study 9802132 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 75
Study 9802132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8589000 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 micrograms/kg/day)
Number of subjects: 39
Study 8589000 — intervention group
Group type: COMPARATOR
Intervention: GM‐CSF (5 micrograms/kg/day)
Number of subjects: 39
Study 8589000 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 39
Study 8589000 — intervention group
Group type: COMPARATOR
Intervention: GM‐CSF
Number of subjects: 39
Study 2474480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside monophosphate
Number of subjects: 43
Study 2474480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 766568 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant ECT
Number of subjects: 0
Study 766568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant ECT
Number of subjects: 0
Study 31410778 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbent cycloergometer training
Number of subjects: 60
Study 31410778 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hyperbaric oxygen therapy
Number of subjects: 60
Study 31410778 — intervention group
Group type: COMPARATOR
Intervention: Control group (without intervention)
Number of subjects: 60
Study 28482137 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 215
Study 28482137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 26112278 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (open-label for 8 weeks, followed by double-blind randomization for 8 weeks)
Number of subjects: 20
Study 26112278 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (open-label extension study up to 52 weeks)
Number of subjects: 20
Study 26112278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind randomization for 8 weeks)
Number of subjects: 20
Study 23111126 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of visual feedback conditions
Number of subjects: 0
Study 23111126 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of region of workspace
Number of subjects: 0
Study 22779693 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg QD
Number of subjects: 705
Study 22779693 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg BID
Number of subjects: 705
Study 22779693 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (all doses)
Number of subjects: 705
Study 22779693 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 705
Study 22779693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 19827645 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipin
Number of subjects: 34
Study 19827645 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril
Number of subjects: 34
Study 19827645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study 17209192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg gluten)
Number of subjects: 49
Study 17209192 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg gluten
Number of subjects: 49
Study 17209192 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg gluten
Number of subjects: 49
Study 15313360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal and nasopharyngeal suctioning before delivery of the shoulders (n=1263)
Number of subjects: 2514
Study 15313360 — intervention group
Group type: COMPARATOR
Intervention: No suctioning before delivery (n=1251)
Number of subjects: 2514
Study 15313360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal and nasopharyngeal suctioning before delivery of the shoulders
Number of subjects: 2514
Study 15313360 — intervention group
Group type: COMPARATOR
Intervention: No suctioning before delivery
Number of subjects: 2514
Study 11677102 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual support (IS) intervention including intensified primary healthcare
Number of subjects: 416
Study 11677102 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 416
Study 9389816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (200 micrograms twice daily)
Number of subjects: 109
Study 9389816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 9389816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 109
Study 8077329 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRHa (deslorelin) administered sc at a dose of 4 micrograms/kg.day for a period of 4 yr
Number of subjects: 43
Study 8077329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3438117 — intervention group
Group type: EXPERIMENTAL
Intervention: General Discrimination Group
Number of subjects: 90
Study 3438117 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Discrimination Group
Number of subjects: 90
Study 3438117 — intervention group
Group type: COMPARATOR
Intervention: Study Skills Group
Number of subjects: 90
Study 30553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal financial incentive (10 Swiss Francs per month)
Number of subjects: 0
Study 30553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Charity financial incentive (10 Swiss Francs per month)
Number of subjects: 0
Study 30553693 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Charity financial incentive
Number of subjects: 0
Study 30553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day and non-usage attrition
Number of subjects: 0
Study 29378703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg twice daily
Number of subjects: 51
Study 29378703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 25 mg/kg every 8 hours (q8h)
Number of subjects: 51
Study 29378703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg every 8 hours (q8h)
Number of subjects: 51
Study 27603346 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin with concurrent radiotherapy (SCCCR)
Number of subjects: 72
Study 27603346 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone with concurrent radiotherapy (CCCR)
Number of subjects: 72
Study 24922488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TAU and neurofeedback (n = 45)
Number of subjects: 71
Study 24922488 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 26)
Number of subjects: 71
Study 22424708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramidal flap design
Number of subjects: 19
Study 22424708 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope flap design
Number of subjects: 19
Study 22424708 — intervention group
Group type: COMPARATOR
Intervention: Triangular flap design
Number of subjects: 19
Study 20864729 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention adapted from Project Sugar 2, involving nurse and community health worker support for diabetes self-management.
Number of subjects: 0
Study 18617079 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of nicotine patches
Number of subjects: 1154
Study 18617079 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of nicotine patches
Number of subjects: 1154
Study 16423095 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention (6 sessions of 30 minutes each)
Number of subjects: 100
Study 16423095 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study 12297208 — intervention group
Group type: EXPERIMENTAL
Intervention: Norsteroid supplementation (224 mg of 19‐nor‐4‐androstene‐3,17‐dione and 120 mg of 19‐nor‐4‐androstene‐3,17‐diol, total daily dose = 344 mg) for 8 weeks
Number of subjects: 10
Study 12297208 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 10
Study 10336913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroanterior electrode position
Number of subjects: 90
Study 10336913 — intervention group
Group type: COMPARATOR
Intervention: Anteroposterior electrode position
Number of subjects: 90
Study 7570331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefotaxime 2 gm
Number of subjects: 775
Study 7570331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study 2229793 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (12 to 15 mg/kg body weight)
Number of subjects: 55
Study 2229793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (1 to 2 mg/kg)
Number of subjects: 55
Study 2229793 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 55
Study 2229793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 55
Study 7437173 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training programme
Number of subjects: 24
Study 7437173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 30649974 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game as a teaching tool
Number of subjects: 46
Study 30649974 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching without the serious game
Number of subjects: 46
Study 28370947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 6 weeks
Number of subjects: 119
Study 28370947 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) for 6 weeks
Number of subjects: 119
Study 26098036 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 620
Study 26098036 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 620
Study 24249359 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing surgery (RRS)
Number of subjects: 691
Study 24249359 — intervention group
Group type: COMPARATOR
Intervention: No risk-reducing surgery (no RRS)
Number of subjects: 691
Study 24249359 — intervention group
Group type: EXPERIMENTAL
Intervention: Any form of RRS
Number of subjects: 691
Study 24249359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of surgery (bilateral mastectomy and ovarian surgery)
Number of subjects: 691
Study 21221045 — intervention group
Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System (in-the-mouth bone conduction device)
Number of subjects: 28
Study 19725251 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg taken once daily for approximately 17 days
Number of subjects: 26
Study 19725251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17151592 — intervention group
Group type: EXPERIMENTAL
Intervention: Foods containing oat beta‐glucan
Number of subjects: 97
Study 17151592 — intervention group
Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 97
Study 15126760 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA group
Number of subjects: 173
Study 15126760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study 11343043 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements, 1 mg/kg/d from 4 to 9 months
Number of subjects: 232
Study 11343043 — intervention group
Group type: COMPARATOR
Intervention: Placebo from 4 to 6 months and iron from 6 to 9 months
Number of subjects: 232
Study 11343043 — intervention group
Group type: COMPARATOR
Intervention: Placebo from 4 to 9 months
Number of subjects: 232
Study 11343043 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements from 6 to 9 months
Number of subjects: 232
Study 9625273 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml) with oral diazepam (5 mg)
Number of subjects: 8
Study 7824501 — intervention group
Group type: EXPERIMENTAL
Intervention: unspecific inhalatory provocation tests
Number of subjects: 0
Study 7824501 — intervention group
Group type: EXPERIMENTAL
Intervention: percentile changes of function parameters
Number of subjects: 0
Study 7824501 — intervention group
Group type: EXPERIMENTAL
Intervention: survival time model
Number of subjects: 0
Study 7824501 — intervention group
Group type: EXPERIMENTAL
Intervention: best case/worst case analysis
Number of subjects: 0
Study 2843130 — intervention group
Group type: EXPERIMENTAL
Intervention: GS + mitomycin C (MMC) 10 mg + adriamycin (ADR) 20 mg (group A, n = 45)
Number of subjects: 112
Study 2843130 — intervention group
Group type: EXPERIMENTAL
Intervention: GS + MMC 10 mg + ADR 20 mg + 200 mg/day of oral 5‐fluorouracil (5‐FU) (group B, n = 36)
Number of subjects: 112
Study 2843130 — intervention group
Group type: COMPARATOR
Intervention: GS + 200 mg/day of 5‐FU (group C, n = 31)
Number of subjects: 112
Study 29297260 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM (1 g/day) with light gymnastic exercise
Number of subjects: 71
Study 29297260 — intervention group
Group type: COMPARATOR
Intervention: Placebo with light gymnastic exercise
Number of subjects: 71
Study 27207203 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS putty alone (Group PUT)
Number of subjects: 20
Study 27207203 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS putty and PRP (Group PRP)
Number of subjects: 20
Study 24906581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha Yoga Group
Number of subjects: 51
Study 24906581 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Group
Number of subjects: 51
Study 24906581 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 51
Study 22225628 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy plus treatment as usual (P + TAU)
Number of subjects: 40
Study 22225628 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study 20358002 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg t.i.d.)
Number of subjects: 51
Study 20358002 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (20 mg b.i.d.)
Number of subjects: 51
Study 20358002 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 51
Study 20358002 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 51
Study 18331364 — intervention group
Group type: EXPERIMENTAL
Intervention: CD203c
Number of subjects: 27
Study 18331364 — intervention group
Group type: EXPERIMENTAL
Intervention: CD63
Number of subjects: 27
Study 15130042 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) used for bonding 121 teeth
Number of subjects: 14
Study 15130042 — intervention group
Group type: COMPARATOR
Intervention: Composite resin used for bonding 121 teeth
Number of subjects: 14
Study 11548979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 11
Study 9661593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable estrogen (E) levels
Number of subjects: 650
Study 9661593 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total testosterone (T) and estrogen (E) levels
Number of subjects: 650
Study 9661593 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary N-telopeptide of type I collagen (NTx) excretion
Number of subjects: 650
Study 9661593 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bioavailable T and E levels
Number of subjects: 650
Study 9661593 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bioavailable E level
Number of subjects: 650
Study 8310510 — intervention group
Group type: EXPERIMENTAL
Intervention: rh‐SOD (200 mg intravenously during surgery)
Number of subjects: 0
Study 3416710 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 159
Study 3416710 — intervention group
Group type: COMPARATOR
Intervention: Other sulfonylureas
Number of subjects: 159
Study 3416710 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 159
Study 31606257 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol/organofunctional silane solution (IOS) treatment
Number of subjects: 600
Study 31606257 — intervention group
Group type: COMPARATOR
Intervention: Nontreated controls
Number of subjects: 600
Study 29542399 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy provided by supervised nurses
Number of subjects: 10
Study 28449212 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ECV (34-36 weeks' gestation)
Number of subjects: 1776
Study 28449212 — intervention group
Group type: COMPARATOR
Intervention: Delayed ECV (at or after 37 weeks)
Number of subjects: 1776
Study 26241529 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 80
Study 26241529 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 80
Study 24441084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein
Number of subjects: 64
Study 24441084 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 64
Study 21435252 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 21148
Study 21435252 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 21148
Study 21435252 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity during leisure time (Men)
Number of subjects: 21148
Study 21435252 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity during leisure time (Women)
Number of subjects: 21148
Study 21435252 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational physical activity (Women)
Number of subjects: 21148
Study 21435252 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of myocardial infarction
Number of subjects: 21148
Study 18429682 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous antegrade ureterolithotripsy
Number of subjects: 91
Study 18429682 — intervention group
Group type: COMPARATOR
Intervention: Retrograde ureterolithotripsy
Number of subjects: 91
Study 16209901 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable shoe (Masai Barefoot Technology, MBT)
Number of subjects: 8
Study 16209901 — intervention group
Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 8
Study 12885095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 5 mg/day, increased by 5 mg/week to a maximum of 30 mg/day for 12 weeks
Number of subjects: 27
Study 12885095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12885095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 27
Study 11533770 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rectal diclofenac immediately after cesarean section followed by 50 mg at 12 hours and 100 mg at 36 hours after surgery
Number of subjects: 40
Study 11533770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diclofenac suppositories)
Number of subjects: 40
Study 9105222 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol sedation (CP)
Number of subjects: 121
Study 9105222 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 121
Study 8415931 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 8415931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8415931 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual caffeine usage
Number of subjects: 0
Study 8415931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (females)
Number of subjects: 0
Study 3698850 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy with carmustine, hydroxycarbamide and dacarbazine before and up to five times after surgery
Number of subjects: 33
Study 3698850 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone
Number of subjects: 33
Study 30815998 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anesthesia
Number of subjects: 120
Study 30815998 — intervention group
Group type: COMPARATOR
Intervention: Light anesthesia
Number of subjects: 120
Study 29618322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential probability ratio test
Number of subjects: 0
Study 29618322 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized incidence ratio
Number of subjects: 0
Study 27184139 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist rescue combined with cabergoline
Number of subjects: 236
Study 27184139 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline alone
Number of subjects: 236
Study 27184139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Antagonist rescue combined with cabergoline and Cabergoline alone)
Number of subjects: 236
Study 25412095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered, self-expanding metal stents (FCSEMSs)
Number of subjects: 50
Study 25412095 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 50
Study 22623316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 56
Study 22623316 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 56